Cargando…

Quantitative Systems Pharmacology Analysis of KRAS G12C Covalent Inhibitors

KRAS has proven difficult to target pharmacologically. Two strategies have recently been described for covalently targeting the most common KRAS mutant in lung cancer, KRAS G12C. Previously, we developed a computational model of the processes that regulate Ras activation. Here, we use this model to...

Descripción completa

Detalles Bibliográficos
Autores principales: Stites, Edward C., Shaw, Andrey S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5980551/
https://www.ncbi.nlm.nih.gov/pubmed/29484842
http://dx.doi.org/10.1002/psp4.12291